Prescription drug policy, 2022 and 2023: the year in review and the year ahead

9 January 2023 - This past year featured many significant developments in the prescription drug policy area, most notably the passage ...

Read more →

Amazon versus Apple: only one will rewrite the rules of health care

29 August 2022 - Big tech has had a surprisingly small impact on U.S. healthcare, so far. ...

Read more →

EMA adopts first list of critical medicines for COVID-19

8 June 2022 - On 7 June 2022, the EMA’s Medicines Shortages Steering Group adopted the list of critical medicines for ...

Read more →

Medicago, Philip Morris and Health Canada: a predictable and avoidable fiasco

22 March 2022 - Health groups urge the Federal government to pressure Medicago to align its approach with that of ...

Read more →

Three doses to be ‘up to date’ as national cabinet prepares for winter waves

10 February 2022 - Top Australian health officials now say people need a third coronavirus vaccine dose to be considered up ...

Read more →

ATAGI update following weekly COVID-19 meeting – 9 February 2022

10 February 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 9 ...

Read more →

Canada's national strategy for drugs for rare diseases needs a holistic approach

8 December 2021 - International report summarises drugs for rare disease best practices and recommendations. ...

Read more →

Pharmaceutical industry backs workplace vaccinations

5 October 2021 - Medicines Australia strongly recommends full COVID-19 vaccinations for the health and safety and protection of all ...

Read more →

Competition, consolidation and evolution in the pharmacy market

12 August 2021 - Implications for efforts to contain drug prices and spending. ...

Read more →

PhRMA's three part approach to build a better health care system

13 April 2021 - Our plan is based on three key pillars: ending the pandemic and building a more resilient system, ...

Read more →

How the FDA stood up to the President

20 October 2020 - Dr. Stephen Hahn, the F.D.A. commissioner, occupies a fraught position, caught between pressure from the White House ...

Read more →

Rare disease therapy development and access remain top FDA priorities during COVID-19

11 June 2020 - The FDA’s work on behalf of people with rare diseases is more important than ever as these ...

Read more →

A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials

16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...

Read more →

Five years on, biosimilars need support from all health care players

6 March 2020 - Today marks a milestone for the U.S. biosimilar market: the FDA approved our first biosimilar, Sandoz’s ...

Read more →

The coronavirus could help pharma reset its reputation in Washington

3 March 2020 - The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington. ...

Read more →